These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27886823)

  • 1. Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention.
    Tricoci P
    Interv Cardiol Clin; 2017 Jan; 6(1):57-66. PubMed ID: 27886823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorapaxar for the reduction of atherothrombotic events.
    Diaz-Ricart M; Escolar G
    Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
    Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
    J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
    Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
    Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular PAR-1: activity and antagonism.
    Lang NN; Guðmundsdóttir IJ; Newby DE
    Cardiovasc Ther; 2011 Dec; 29(6):349-61. PubMed ID: 20528879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.
    Gurbel PA; Bliden KP; Turner SE; Tantry US; Gesheff MG; Barr TP; Covic L; Kuliopulos A
    Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):189-97. PubMed ID: 26681756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
    Ungar L; Rodriguez F; Mahaffey KW
    Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.